Clinical trial
Study of Oral PG-116800 Following a Heart Attack
NCT00067236 · Procter and Gamble, Industry · Completed
Key facts
| NCT number | NCT00067236 |
|---|---|
| Title | Study of Oral PG-116800 Following a Heart Attack |
| Official title | A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Oral PG-116800 Following a Heart Attack |
| Lead sponsor | Procter and Gamble, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myocardial Infarction, Heart Failure, Heart Enlargement |
| Intervention type | Drug |
| Interventions | PG-116800 (given as PG-530742), Placebo tablet |
| Enrollment | 253 |
| Start date | Sep 1, 2003 |
| Primary completion | Dec 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Aug 14, 2003 |
| Last update posted | Nov 4, 2011 |
| Countries | Canada, Poland, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: